期刊文献+

慢性丙型肝炎铁代谢的失调机制 被引量:9

Mechanism of iron metabolism disorder in patients with chronic hepatitis C
在线阅读 下载PDF
导出
摘要 肝脏是人体储存铁离子的主要器官,因此铁离子代谢失常与慢性肝炎密切相关。目前,慢性丙型肝炎(CHC)中铁离子过载的机制并没有完全阐明。铁调素调控非常复杂,依赖于许多变量,包括不同阶段的肝脏炎症情况、转铁蛋白参与的铁离子循环以及胞内铁离子储存等,这些因素都与引起HCV相关肝脏疾病患者中铁离子浓度的变化有关。讨论了系统铁离子稳态的调控、CHC与铁离子失调的关系及诱发CHC铁离子过载的机制。认为深入认识铁离子稳态和相关信号通路之间的关系将促进HCV相关疾病的控制与治疗。 Since the liver is the major iron storage organ in human body, iron metabolism disorder is closely related to chronic hepatitis. So far, the mechanisms underlying iron overload in chronic hepatitis C (CHC) have not been fully elucidated. Highly complex regulation of hepcidin relies on a number of variables, including hepatic inflammatory conditions of different stages, transferrin - bound iron circulation, and intracellular iron storage. All these factors are associated with variations in hepatic iron concentrations among patients with hepatitis C vi- rus (HCV) -related chronic liver disease. This paper discusses the regulation of systemic iron homeostasis, the relationship between CHC and iron metabolism disorder, and the mechanism of inducing iron overload. In - depth understanding about iron homeostasis and the rela- tionship between relevant signaling pathways will contribute to the control and therapy of HCV - related diseases.
出处 《临床肝胆病杂志》 CAS 2015年第2期291-294,共4页 Journal of Clinical Hepatology
关键词 肝炎 丙型 慢性 受体 转铁蛋白 铁蛋白质类 铁代谢障碍 综述 hepatiitis C, chronic iron overload receptors, transferrin iron metabolism disorders review
作者简介 秦源(1985-),男,实验员,主要从事HCV感染机制的研究。 通信作者:贾战生,电子信箱:jiazsh@fmmu.edu.cn。
  • 相关文献

参考文献40

  • 1钟劲,陶万银.直接抗病毒药物时代下丙型肝炎研究面临的挑战[J].临床肝胆病杂志,2014,30(6):481-484. 被引量:9
  • 2TANAKA H, FUJITA N, SUGIMOTO R, et al. Hepatic oxida- tive DNA damage is associated with increased risk for hepa- tocellular carcinoma in chronic hepatitis C[ J]. Br J Cancer, 2008, 98(3) : 580 -586.
  • 3THURSZ M. Iron, haemochromatosis and thalassaemia as risk factors for fibrosis in hepatitis C virus infectiobn [J ]. Gut, 2007, 56(5) : 613 -614.
  • 4LIU HY, TRINH TL, DONG H J, et al. Iron regulator hepcidin exhibits antiviral activity against hepatitis C virus [ J ]. PLoS Qne, 2012, 7(10) : e46631.
  • 5SHE HY, XlONG S, LIN M, et al. Iron activates NF -kappaB in Kupffer cells[J]. Am J Physiol Gastrointest Liver Physiol, 2002, 283(3) : g719 -g726.
  • 6HENTZE MW, MUCKENTHALER MU, ANDREWS NC. Bal- ancing acts: molecular control of mammalian iron metabolism [J]. Cell, 2004, 117(3) : 285 -297.
  • 7GANZ T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation [ J ]. Blood, 2003, 102 (3) : 783 -788.
  • 8LIU Y, AN DZ, SUN R. Inhibition of translation initiation fac- tors might be the potential therapeutic targets for HCV pa- tients with hepatic iron overload [ J ]. Med Hypotheses, 2012, 78(1 ) : 142 -143.
  • 9ROE MA, COLLINGS R, DAINTY JR, et al. Plasma hepcidinconcentrations significantly predict interindividual variation in iron absorption in healthy men[J]. Am J Clin Nutr, 2009, 89 (4) : 1088-1091.
  • 10NEMETH E, TUTTLE MS, PQWELSON J, et al. Hepcidin regu- lates cellular iron efflux by binding to ferroportin and inducing its internalization[J]. Science, 2004, 306(5704}: 2090 -2093.

二级参考文献33

  • 1WHO. Guidelines for the screening, care and treatment of persons with hepatitis C infection[ M]. WHO Press, 2014: 5 -122.
  • 2SMITH DB, BUKH J, KUIKEN C, et al. Expanded classifica- tion of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment Web resource[ J ]. Hepatology, 2014, 59(1 ) : 318 -327.
  • 3THOMAS DL. Global control of hepatitis C: where challenge meets opportunity[J]. Nat Med, 2013, 19(7) : 850 -858.
  • 4MANNS MP, von HAHN T. Novel therapies for hepatitis C -one pill fits all? [J]. Nat Rev Drug Discov, 2013, 12(8): 595 -610.
  • 5ENOMOTO N, SAKUMA I, ASAHINA Y, et al. Comparison of full- length sequences of interferon -sensitive and resist- ant hepatitis C virus 1 b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region[J]. J Clin In- vest, 1995, 96(1): 224-230.
  • 6RAO H, WEI L, LOPEZ -TALAVERA JC, et al. Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection [ J ]. J Gastro- enterol Hepatol, 2014, 29(3): 545-553.
  • 7SHI X, PAN Y, WANG M, et al. IL28B genetic variation is associated with spontaneous clearance of hepatitis C virus, treatment response, serum IL-28B levels in Chinese popu- lation[J]. PLoS One, 2012, 7(5) : e37054.
  • 8THOMAS DL, THIO CL, MARTIN MP, et al. Genetic varia- tion in IL28B and spontaneous clearance of hepatitis C virus [J]. Nature, 2009, 461 (7265):798-801.
  • 9TANAKA Y, NISHIDA N, SUGIYAMA M, et al. Genome - wide association of IL28B with response to pegylated inter- feron -alpha and ribavirin therapy for chronic hepatitis C [ J ]. Nat Genet, 2009, 41 (10) : 1105 -1109.
  • 10SUPPIAH V, MOLDOVAN M, AHLENSTIEL G, et al. IL28B is associated with response to chronic hepatitis C interferon -alpha and ribavirin therapy[J]. Nat Genet, 2009, 41 (10) : 1100 -1104.

共引文献18

同被引文献77

引证文献9

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部